Search research articles
Contact Us
Filters
Showing results (71-80 of 110) with videos related to
Page
of 11
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 1995
Lipopolysaccharide-induced hypotension and vascular hyporeactivity in the rat: tissue analysis of nitric oxide synthase mRNA and protein expression in the presence and absence of dexamethasone, NG-monomethyl-L-arginine or indomethacin
G J Hom, S K Grant, G Wolfe, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|
December 1, 1990
Evidence that circulating 6keto prostaglandin E1 causes the platelet defect of Bartter's syndrome
D M Clive, J S Stoff, M Cardi, et al.
Blood
|
April 1, 1984
Inhibition of platelet function by cis-unsaturated fatty acids
D E MacIntyre, R L Hoover, M Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 10, 1998
Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor
D S Fletcher, M R Candelore, D Grujic, et al.
The Journal of Experimental Medicine
|
December 1, 1993
Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8
R Meurer, G Van Riper, W Feeney, et al.
Neuroscience
|
September 18, 2007
Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses
J Menetski, S Mistry, M Lu, et al.
Agents and Actions. Supplements
|
January 1, 1986
Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators
D E MacIntyre, M Bushfield, L J MacMillan, et al.
Advances in Prostaglandin and Thromboxane Research
|
January 1, 1980
Is the platelet defect in Bartter's syndrome associated with a plasma prostaglandin?
D E MacIntyre, M Smith, L Levine, et al.
Journal of Medicinal Chemistry
|
May 1, 1989
2,3-Dihydro-5-benzofuranols as antioxidant-based inhibitors of leukotriene biosynthesis
M L Hammond, I E Kopka, R A Zambias, et al.
Molecular Pharmacology
|
July 1, 1991
5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors
J F Evans, C Lévillé, J A Mancini, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 110) with videos related to
Sort By:
Page
of 11
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 1995
Lipopolysaccharide-induced hypotension and vascular hyporeactivity in the rat: tissue analysis of nitric oxide synthase mRNA and protein expression in the presence and absence of dexamethasone, NG-monomethyl-L-arginine or indomethacin
G J Hom, S K Grant, G Wolfe, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|
December 1, 1990
Evidence that circulating 6keto prostaglandin E1 causes the platelet defect of Bartter's syndrome
D M Clive, J S Stoff, M Cardi, et al.
Blood
|
April 1, 1984
Inhibition of platelet function by cis-unsaturated fatty acids
D E MacIntyre, R L Hoover, M Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 10, 1998
Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor
D S Fletcher, M R Candelore, D Grujic, et al.
The Journal of Experimental Medicine
|
December 1, 1993
Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8
R Meurer, G Van Riper, W Feeney, et al.
Neuroscience
|
September 18, 2007
Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses
J Menetski, S Mistry, M Lu, et al.
Agents and Actions. Supplements
|
January 1, 1986
Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators
D E MacIntyre, M Bushfield, L J MacMillan, et al.
Advances in Prostaglandin and Thromboxane Research
|
January 1, 1980
Is the platelet defect in Bartter's syndrome associated with a plasma prostaglandin?
D E MacIntyre, M Smith, L Levine, et al.
Journal of Medicinal Chemistry
|
May 1, 1989
2,3-Dihydro-5-benzofuranols as antioxidant-based inhibitors of leukotriene biosynthesis
M L Hammond, I E Kopka, R A Zambias, et al.
Molecular Pharmacology
|
July 1, 1991
5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors
J F Evans, C Lévillé, J A Mancini, et al.
Page
of 11